Zacks Research Has Pessimistic View of A Q1 Earnings

Agilent Technologies, Inc. (NYSE:A) – Equities research analysts at Zacks Research cut their Q1 2025 earnings estimates for shares of Agilent Technologies in a note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $1.27 per share for the quarter, down from their previous forecast of $1.38. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Zacks Research also issued estimates for Agilent Technologies’ Q2 2025 earnings at $1.33 EPS, Q4 2025 earnings at $1.55 EPS, FY2025 earnings at $5.55 EPS, Q1 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.58 EPS and FY2026 earnings at $6.10 EPS.

A number of other equities analysts have also weighed in on A. Wells Fargo & Company reduced their target price on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. UBS Group upped their price objective on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. StockNews.com downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Finally, TD Cowen raised their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies has an average rating of “Hold” and an average target price of $143.62.

Agilent Technologies Stock Down 1.3 %

Shares of Agilent Technologies stock opened at $139.05 on Friday. The company has a market capitalization of $39.95 billion, a P/E ratio of 31.45, a price-to-earnings-growth ratio of 4.48 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. The business has a 50-day moving average of $136.87 and a two-hundred day moving average of $136.60. Agilent Technologies has a 1 year low of $124.16 and a 1 year high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The business had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. Agilent Technologies’s revenue for the quarter was up .8% on a year-over-year basis. During the same period last year, the company posted $1.38 EPS.

Hedge Funds Weigh In On Agilent Technologies

Several hedge funds and other institutional investors have recently modified their holdings of A. Tidal Investments LLC lifted its stake in Agilent Technologies by 8.2% in the 3rd quarter. Tidal Investments LLC now owns 14,752 shares of the medical research company’s stock valued at $2,187,000 after purchasing an additional 1,113 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Agilent Technologies during the 3rd quarter valued at $535,000. World Investment Advisors LLC boosted its holdings in shares of Agilent Technologies by 4.7% during the 3rd quarter. World Investment Advisors LLC now owns 4,466 shares of the medical research company’s stock valued at $663,000 after acquiring an additional 201 shares in the last quarter. SkyView Investment Advisors LLC grew its position in Agilent Technologies by 5.2% during the 3rd quarter. SkyView Investment Advisors LLC now owns 3,615 shares of the medical research company’s stock worth $537,000 after acquiring an additional 178 shares during the last quarter. Finally, Rehmann Capital Advisory Group bought a new position in Agilent Technologies in the third quarter valued at about $236,000. Institutional investors own 87.42% of the company’s stock.

Insider Buying and Selling at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.33% of the company’s stock.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.99 annualized dividend and a yield of 0.71%. Agilent Technologies’s payout ratio is 22.40%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.